Green synthesis of nanoparticles using botanicals and their application in management of fungal phytopathogens: a review.

Green synthesis of nanoparticles is an emerging aspect in plant disease management that blends nanotechnology and plant-derived ingredients to produce a biocontrol formulation. Different physical and chemical processes employed in the synthesis of nanoparticles are polluting, expensive, and also release hazardous by- products. The range of secondary metabolites present in plants makes them efficient reducing and stabilizing agent during the synthesis process. These metabolites serve a vital role in plant defense against the invasion of phytopathogens including fungi, bacteria, viruses, insect pests, etc. The plant metabolites, such as sugars, terpenoids, polyphenols, alkaloids, phenolic acids, and proteins, have been shown to be crucial in the reduction of metal ions into nanoparticles. In green synthesis of nanoparticles, the plant extracts are used as potential reducing and capping. This also restricts the formation of clusters or aggregates and improves the colloidal stability. The nanoparticles exhibit excellent antimycotic against a variety of phytopathogens and are very efficient in managing plant diseases. The aim of this review is to highlight plants, phytochemicals exhibiting antifungal properties, green synthesis of nanoparticles using plant material and their antimycotic activity.

Clinical Presentation, Investigation and Control of an Outbreak of Adenoviral Conjunctivitis in a Neonatal Unit at a Tertiary Hospital.

BACKGROUND: Nosocomial spread of adenovirus infection has been reported in neonatal, pediatric and adult medical units. This nonenveloped and hardy virus is resistant to numerous disinfectants thus posing a challenge for control and prevention of adenovirus infections in health care settings. METHODS: An epidemiologic outbreak investigation revealed an adenoviral outbreak in the neonatal nursery as well as in the neonatal screening outpatient department for Retinopathy of Prematurity (ROP). All suspected cases (94 neonates) underwent adenoviral conventional polymerase chain reaction (PCR) and representative samples underwent sequencing by Sanger's method. The clinical features and disease course were studied. Infected babies were started on tobramycin eye drops. Topical steroid eye drops were added for those who developed pseudomembranes. RESULTS: We found 58 cases of laboratory-confirmed neonatal adenovirus conjunctivitis (between July 10 and October 24, 2019). Redness (96%) was the most common presentation followed by discharge (68.9%) and lid edema (51.7%). Pseudomembrane were seen in 77.5% of the infected neonates. Prior ROP examination was carried out in 38 (65.5%) neonates. Respiratory symptoms were present in 7 (12.06%) neonates. Sequencing revealed serotype 8 as the cause of the outbreak. Control measures were strictly implemented. Standard Operating Procedures (SOPs) for ROP screening were revisited, revised and reinforced to prevent future outbreaks. CONCLUSIONS: We observed ROP screening as a risk factor for the development of adenoviral conjunctivitis in neonatal care units. Neonates present with different clinical manifestations as compared with adults. Prompt control measures were implemented to control the adenoviral outbreak.

No Traces of SARS-CoV-2 In Wounds of COVID-19 Positive Patients: A Pilot Study.

Background This study was performed to investigate the presence of SARS-CoV-2 virus in wounds of COVID-19 positive patients. Methods This is a single-center observational study. COVID-19 patients with wounds (traumatic/infective/surgical) were included in this study. Preoperative, intraoperative, or postoperative specimens were collected and analyzed with real-time reverse transcriptase polymerase chain reaction (rRT-PCR) to know the presence of the virus. Results A total of eight patients were included in this study. Eleven samples were collected (seven wound swabs, two peritoneal fluids, and two tissue specimens) and analyzed. None of the samples from the wound tested positive for the virus while they were tested positive for nasal swab taken simultaneously or within 3 days prior. Conclusion The wounds of COVID-19 patients are considered negative and can be managed with routine wound precautions.